MannKind Corp. (MNKD) will be presenting new clinical and real-world data related to Afrezza on March 12 &14 at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026).
Afrezza Inhalation Powder is the only ultra-rapid-acting inhaled insulin approved by the FDA to improve glycemic control in adult patients with diabetes mellitus. Administered at the beginning of meals using a small, portable inhaler, Afrezza delivers insulin via MannKind's proprietary Technosphere technology, enabling ultra-rapid absorption through the lungs.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.